A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
Epistemonikos ID: 3738808519db06f8d8f551e7b16d7d3322417488
First added on: Oct 03, 2023